Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Macpherson

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Hypertension (Dallas, Tex. : 1979)|May 1, 1991
Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanismS A Griffin, W C Brown, F MacPherson, et al.
The International Journal of Eating Disorders|July 1, 1993
Comparison of eating disorders and other dietary/weight groups on measures of perceived control, assertiveness, self-esteem, and self-directed hostilityG J Williams, K G Power, H R Millar, et al.
Infectious Diseases and Therapy|June 17, 2023
Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 TrialHimanshu P Upadhyaya, Jenny Y Chien, Amanda J Long, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Hypertension (Dallas, Tex. : 1979)|May 1, 1991
Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanismS A Griffin, W C Brown, F MacPherson, et al.
The International Journal of Eating Disorders|July 1, 1993
Comparison of eating disorders and other dietary/weight groups on measures of perceived control, assertiveness, self-esteem, and self-directed hostilityG J Williams, K G Power, H R Millar, et al.
Infectious Diseases and Therapy|June 17, 2023
Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 TrialHimanshu P Upadhyaya, Jenny Y Chien, Amanda J Long, et al.
Pageof 6